GlobalData

The healthcare industry reported 125 VC deals worth $2.7 billion in May 2023, compared to the last 12-month average (May 2022 to…

It is expected that the prescribing patterns of Rinvoq by HCPs will follow an ongoing trend by gastroenterologists to be more…

HTIT has recently submitted a marketing authorisation application in China for first oral insulin for type 2 diabetes

The need for disease-modifying therapies is one of the highest unmet needs and if a curative or disease-modifying agent was…

GlobalData’s latest report, "Thematic Research: Immuno-Oncology” explores the IO pipeline and identifies over 700 novel agents…

UX053 was one of five non-vaccine mRNA therapeutics in clinical trial development. The other four are all currently in Phase I/II…

VC investments decreased by 45.8 per cent in April 2023, compared to April 2022

The R&D setbacks in the women’s health space have ultimately led to Bayer refocussing its research efforts on oncology,…

Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01…

Tolebrutinib is expected to be the leading BTK inhibitor by 2030, with forecasted sales of approximately $2.6B across the 7MM